The long noncoding RNA TARID regulates the CXCL3/ERK/MAPK pathway in trophoblasts and is associated with preeclampsia
Minda Zhang, Zeyu Shi, Shuaishuai Zhang, Xudan Li, Sally Kit Yan To, Yijia Peng, Jie Liu, Siming Chen, Hongyu Hu, Alice Sze Tsai Wong, Jin-Zhang Zeng
Journal:Cancers
IF:6.58
DOI:10.3390/cancers15010024
PMID:36612021
Published:2022-12-20
research field:肿瘤学分子生物学药理学生物化学
Abstract
Drug-resistant epilepsy patients has aberrant inflammatory mediator levels. However, the mechanism of which is remains unillustrated. Here the molecular mechanism underlying the neuroinflammatory process in patients with drug-resistant epilepsy were investigated. Bioinformatics analysis revealed that miR-34c-5p was significantly downregulated in patients with drug-resistant epilepsy, compared to control population. Then, luciferase reporter assays indicated that HMGB1, inflammation-related mediators, was the target gene of miR-34c-5p. The kainic acid-induced epileptic rats were established and divided into drug-sensitive epilepsy and drug-resistant epilepsy according to their seizure behavior and EEG after antiepileptic drug administration. Downregulation of miR-34c-5p, elevated expression of HMGB1 and IL-1β had been found in rats with drug-resistant epilepsy, compared to drug-sensitive epilepsy rats. Aggravated hippocampal neuron loss was demonstrated in rats with drug-resistant epilepsy. The results from epileptic rats were subsequently validated from children with drug-resistant epilepsy. Analysis manifested that miR-34c-5p was obviously decreased, while HMGB1 was increased on serum of children with drug-resistant epilepsy. Our study highlights that decreased miR-34c-5p in drug-resistant epilepsy exacerbates neuroinflammation, which aggravates hippocampal neuron loss in epileptogenesis. Thus, miR-34c-5p could be considered as a potential noninvasive biomarker and shed novel light on the development of an effective therapeutic strategy for children with drug-resistant epilepsy in the future.
本文使用的Yeasen产品


